118 related articles for article (PubMed ID: 17082012)
21. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
22. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
[TBL] [Abstract][Full Text] [Related]
24. Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Carney DA; Seymour JF
Leuk Lymphoma; 2010 Nov; 51(11):1957-9. PubMed ID: 20858101
[No Abstract] [Full Text] [Related]
25. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
26. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
27. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
29. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
Malagola M; Peli A; Damiani D; Candoni A; Tiribelli M; Martinelli G; Piccaluga PP; Paolini S; De Rosa F; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filì C; Fanin R; Baccarani M; Russo D
Eur J Haematol; 2008 Nov; 81(5):354-63. PubMed ID: 18637030
[TBL] [Abstract][Full Text] [Related]
30. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
[TBL] [Abstract][Full Text] [Related]
31. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
32. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
33. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia.
Park TS; Cheong JW; Song J; Choi JR
Leuk Res; 2009 Jul; 33(7):1001-4. PubMed ID: 19155067
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
[TBL] [Abstract][Full Text] [Related]
35. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
[TBL] [Abstract][Full Text] [Related]
36. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
[TBL] [Abstract][Full Text] [Related]
37. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
Coso D; Costello R; Cohen-Valensi R; Sainty D; Nezri M; Gastaut JA; Bouabdallah R
Ann Oncol; 1999 Mar; 10(3):362-3. PubMed ID: 10355587
[No Abstract] [Full Text] [Related]
39. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
40. Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
MacCallum S; Groves M; Brass D; Cunningham J; Sales M; Gelly K; Tauro S
J Clin Pathol; 2009 May; 62(5):468-70. PubMed ID: 19398596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
